Browse by category

A Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the largest real-world studies to date examining obesity treatment use and long-term weight changes after GLP-1 discontinuation, researchers at Cleveland Clinic found that many patients s

Fractyl Health has announced positive early data from the open-label REVEAL-1 cohort of its ongoing REMAIN-1 pivotal study. The results...